NUVL
Price
$105.76
Change
+$0.93 (+0.89%)
Updated
Dec 24 closing price
Capitalization
8.21B
69 days until earnings call
Intraday BUY SELL Signals
VRDN
Price
$32.28
Change
+$0.17 (+0.53%)
Updated
Dec 24 closing price
Capitalization
3.08B
70 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NUVL vs VRDN

Header iconNUVL vs VRDN Comparison
Open Charts NUVL vs VRDNBanner chart's image
Nuvalent
Price$105.76
Change+$0.93 (+0.89%)
Volume$134.51K
Capitalization8.21B
Viridian Therapeutics
Price$32.28
Change+$0.17 (+0.53%)
Volume$403.58K
Capitalization3.08B
NUVL vs VRDN Comparison Chart in %
NUVL
Daily Signal:
Gain/Loss:
VRDN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NUVL vs. VRDN commentary
Dec 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Buy and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 25, 2025
Stock price -- (NUVL: $105.76 vs. VRDN: $32.28)
Brand notoriety: NUVL and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 20% vs. VRDN: 22%
Market capitalization -- NUVL: $8.21B vs. VRDN: $3.08B
NUVL [@Biotechnology] is valued at $8.21B. VRDN’s [@Biotechnology] market capitalization is $3.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 3 bullish TA indicator(s).

  • NUVL’s TA Score: 5 bullish, 3 bearish.
  • VRDN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than VRDN.

Price Growth

NUVL (@Biotechnology) experienced а +4.45% price change this week, while VRDN (@Biotechnology) price change was +0.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

VRDN is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($8.21B) has a higher market cap than VRDN($3.08B). VRDN YTD gains are higher at: 68.388 vs. NUVL (35.105). VRDN has higher annual earnings (EBITDA): -298.48M vs. NUVL (-398.38M). NUVL has more cash in the bank: 943M vs. VRDN (491M). VRDN has higher revenues than NUVL: VRDN (70.8M) vs NUVL (0).
NUVLVRDNNUVL / VRDN
Capitalization8.21B3.08B267%
EBITDA-398.38M-298.48M133%
Gain YTD35.10568.38851%
P/E RatioN/AN/A-
Revenue070.8M-
Total Cash943M491M192%
Total DebtN/A21.6M-
FUNDAMENTALS RATINGS
VRDN: Fundamental Ratings
VRDN
OUTLOOK RATING
1..100
76
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
PROFIT vs RISK RATING
1..100
62
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NUVLVRDN
RSI
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
77%
Bearish Trend 8 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signal:
Gain/Loss:
VRDN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VVILX28.460.09
+0.32%
Vulcan Value Partners Institutional
PGRCX46.880.09
+0.19%
BNY Mellon Worldwide Growth C
QUAYX79.970.09
+0.11%
AB Small Cap Growth Advisor
FNIAX46.43N/A
N/A
Fidelity Advisor New Insights A
GGSOX16.29N/A
N/A
Grandeur Peak Global Stalwarts Investor

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with RVMD. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+0.89%
RVMD - NUVL
62%
Loosely correlated
+1.15%
XNCR - NUVL
60%
Loosely correlated
-0.13%
IDYA - NUVL
58%
Loosely correlated
+0.76%
VRDN - NUVL
58%
Loosely correlated
+0.53%
XENE - NUVL
56%
Loosely correlated
+1.06%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with NUVL. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+0.53%
NUVL - VRDN
58%
Loosely correlated
+0.89%
XNCR - VRDN
56%
Loosely correlated
-0.13%
CLDX - VRDN
54%
Loosely correlated
+0.94%
SYRE - VRDN
54%
Loosely correlated
-0.54%
RVMD - VRDN
51%
Loosely correlated
+1.15%
More